Synergy Pharmaceuticals Inc.’s (SGYP) New Drug Application for Plecanatide for the treatment of chronic idiopathic constipation has been accepted for review by the FDA.
The regulatory agency’s decision date is set for January 29, 2017.
MOH Opens Wallet, PFE’s Ibrance A Step Closer To Full Approval, SGYP To Face FDA
